| Id: | acc2077 |
| Group: | 2sens |
| Protein: | FAK |
| Gene Symbol: | PTK2 |
| Protein Id: | Q05397 |
| Protein Name: | FAK1_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr |
| Site Sequence: | |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | MDA-MB-231 |
| Disease Info: | |
| Drug: | Met-F-AEA |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | "Met-F-AEA treatment inhibits the invasion and metastasis of tumor cells, and the tyrosine phosphorylation of both FAK and Src decreases." |
| Note: | site unclear |
| Score: | 4.0 |
| Pubmed(PMID): | 16343481 |
| Sentence Index: | 16343481_6-7 |
| Sentence: | "In Met-F-AEA-treated cells, we observed a decreased tyrosine phosphorylation of both FAK and Src, this effect being attenuated by SR141716A. We propose that CB1 receptor agonists inhibit tumor cell invasion and metastasis by modulating FAK phosphorylation, and that CB1 receptor activation might represent a novel therapeutic strategy to slow down the growth of breast carcinoma and to inhibit its metastatic diffusion in vivo." |
Sequence & Structure:
MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 3 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Terminated | malignant pleural mesothelioma | ClinicalTrials ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | multiple myeloma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic carcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | thyroid carcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Completed | non-small cell lung carcinoma | ClinicalTrials ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | ovarian serous adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic adenocarcinoma | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Completed | pancreatic adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | Uveal Melanoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | pancreatic ductal adenocarcinoma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Not yet recruiting | colorectal cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Active, not recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | ovarian cancer | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Completed | lung cancer | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | meningioma | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | female reproductive system neoplasm | ClinicalTrials |
| PTK2 | GSK-2256098 | Focal adhesion kinase 1 inhibitor | 2 | Recruiting | intracranial meningioma | ClinicalTrials |
| PTK2 | VS-4718 | Focal adhesion kinase 1 inhibitor | 1 | Withdrawn | B-cell acute lymphoblastic leukemia | ClinicalTrials |
| PTK2 | VS-4718 | Focal adhesion kinase 1 inhibitor | 1 | Withdrawn | acute myeloid leukemia | ClinicalTrials |
| PTK2 | DEFACTINIB | Focal adhesion kinase 1 inhibitor | 1 | Active, not recruiting | endometrioid carcinoma | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 1 | Not yet recruiting | neoplasm | ClinicalTrials |
| PTK2 | IFEBEMTINIB | Focal adhesion kinase 1 inhibitor | 1 | Recruiting | neoplasm | ClinicalTrials ClinicalTrials |
| PTK2 | CEP-37440 | Focal adhesion kinase 1 inhibitor | 1 | Completed | neoplasm | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| PTK2-Ser29 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -2.43 | ||||||||
| COAD | |||||||||
| HGSC | 0.863 | ||||||||
| ccRCC | 0.19 | ||||||||
| GBM | 0.396 | ||||||||
| HNSC | 0.598 | ||||||||
| LUAD | 0.118 | ||||||||
| LUSC | 0.436 | ||||||||
| non_ccRCC | 0.958 | ||||||||
| PDAC | -0.426 | ||||||||
| UCEC | -0.703 | ||||||||
| PTK2-Ser390 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.882 | ||||||||
| HGSC | -1.086 | ||||||||
| ccRCC | |||||||||
| GBM | 0.204 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser392 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -0.683 | ||||||||
| ccRCC | |||||||||
| GBM | 0.311 | ||||||||
| HNSC | 0.961 | ||||||||
| LUAD | -1.376 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.788 | ||||||||
| PTK2-Ser568 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | 0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser702 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.863 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.233 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | -1.096 | ||||||||
| UCEC | |||||||||
| PTK2-Ser705 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.692 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.067 | ||||||||
| LUAD | -0.651 | ||||||||
| LUSC | -0.337 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.772 | ||||||||
| UCEC | |||||||||
| PTK2-Ser708 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.97 | ||||||||
| COAD | 0.049 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.154 | ||||||||
| GBM | |||||||||
| HNSC | 0.406 | ||||||||
| LUAD | -0.561 | ||||||||
| LUSC | -0.32 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -1.581 | ||||||||
| UCEC | -0.117 | ||||||||
| PTK2-Ser716 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -1.009 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.14 | ||||||||
| GBM | 0.356 | ||||||||
| HNSC | 1.419 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.907 | ||||||||
| PTK2-Ser722 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.265 | ||||||||
| HGSC | 2.089 | ||||||||
| ccRCC | |||||||||
| GBM | 0.333 | ||||||||
| HNSC | |||||||||
| LUAD | -0.894 | ||||||||
| LUSC | |||||||||
| non_ccRCC | -0.375 | ||||||||
| PDAC | -0.199 | ||||||||
| UCEC | -0.689 | ||||||||
| PTK2-Ser840 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 1.141 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.13 | ||||||||
| GBM | |||||||||
| HNSC | 0.246 | ||||||||
| LUAD | 0.299 | ||||||||
| LUSC | -0.2 | ||||||||
| non_ccRCC | |||||||||
| PDAC | 0.659 | ||||||||
| UCEC | -2.014 | ||||||||
| PTK2-Ser843 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.028 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.136 | ||||||||
| GBM | 1.188 | ||||||||
| HNSC | 0.169 | ||||||||
| LUAD | 0.224 | ||||||||
| LUSC | 0.928 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.267 | ||||||||
| UCEC | -2.135 | ||||||||
| PTK2-Ser850 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.344 | ||||||||
| HGSC | |||||||||
| ccRCC | -1.085 | ||||||||
| GBM | |||||||||
| HNSC | -0.475 | ||||||||
| LUAD | 1.216 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Ser910 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.569 | ||||||||
| COAD | -0.212 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.358 | ||||||||
| GBM | -0.058 | ||||||||
| HNSC | 0.662 | ||||||||
| LUAD | -0.174 | ||||||||
| LUSC | 0.71 | ||||||||
| non_ccRCC | -1.419 | ||||||||
| PDAC | 0.888 | ||||||||
| UCEC | -1.609 | ||||||||
| PTK2-Thr394 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.36 | ||||||||
| HGSC | -1.442 | ||||||||
| ccRCC | |||||||||
| GBM | 0.277 | ||||||||
| HNSC | 0.237 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 1.288 | ||||||||
| PTK2-Thr575 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | -1.145 | ||||||||
| ccRCC | 0.703 | ||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.442 | ||||||||
| PTK2-Thr914 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.707 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | -0.707 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Tyr397 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.587 | ||||||||
| HGSC | -1.155 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | 0.567 | ||||||||
| PTK2-Tyr570 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | -0.018 | ||||||||
| COAD | 0.395 | ||||||||
| HGSC | 1.385 | ||||||||
| ccRCC | 0.37 | ||||||||
| GBM | -0.571 | ||||||||
| HNSC | -0.744 | ||||||||
| LUAD | -1.592 | ||||||||
| LUSC | -0.966 | ||||||||
| non_ccRCC | 0.897 | ||||||||
| PDAC | 1.49 | ||||||||
| UCEC | -0.646 | ||||||||
| PTK2-Tyr576 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.473 | ||||||||
| HGSC | 1.142 | ||||||||
| ccRCC | |||||||||
| GBM | -0.517 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -1.098 | ||||||||
| PTK2-Tyr577 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 1.045 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.097 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.948 | ||||||||
| PTK2-Tyr720 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.364 | ||||||||
| HGSC | 1.575 | ||||||||
| ccRCC | |||||||||
| GBM | 0.353 | ||||||||
| HNSC | |||||||||
| LUAD | -0.64 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | -0.923 | ||||||||
| PTK2-Tyr861 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.904 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -1.074 | ||||||||
| HNSC | 0.17 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2-Tyr925 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.981 | ||||||||
| GBM | 0.023 | ||||||||
| HNSC | |||||||||
| LUAD | 0.293 | ||||||||
| LUSC | 0.993 | ||||||||
| non_ccRCC | 0.192 | ||||||||
| PDAC | -1.892 | ||||||||
| UCEC | -0.59 | ||||||||
| PTK2B-Ser361 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | 0.707 | ||||||||
| LUSC | -0.707 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser375 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.873 | ||||||||
| COAD | -0.141 | ||||||||
| HGSC | 2.388 | ||||||||
| ccRCC | -0.73 | ||||||||
| GBM | -0.066 | ||||||||
| HNSC | -0.489 | ||||||||
| LUAD | 0.023 | ||||||||
| LUSC | 0.434 | ||||||||
| non_ccRCC | -0.383 | ||||||||
| PDAC | -1.494 | ||||||||
| UCEC | -0.416 | ||||||||
| PTK2B-Ser571 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | 0.707 | ||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser746 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.625 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 1.153 | ||||||||
| HNSC | -0.528 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser747 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.707 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | |||||||||
| HNSC | 0.707 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser758 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 1.122 | ||||||||
| GBM | -0.326 | ||||||||
| HNSC | -0.796 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser762 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | -0.33 | ||||||||
| HGSC | |||||||||
| ccRCC | -0.021 | ||||||||
| GBM | -0.325 | ||||||||
| HNSC | -0.996 | ||||||||
| LUAD | 1.671 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Ser778 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.482 | ||||||||
| COAD | -0.158 | ||||||||
| HGSC | 2.376 | ||||||||
| ccRCC | -0.259 | ||||||||
| GBM | -0.528 | ||||||||
| HNSC | -0.202 | ||||||||
| LUAD | -0.526 | ||||||||
| LUSC | 0.229 | ||||||||
| non_ccRCC | 0.124 | ||||||||
| PDAC | -1.539 | ||||||||
| UCEC | |||||||||
| PTK2B-Ser839 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | 1.459 | ||||||||
| ccRCC | -1.431 | ||||||||
| GBM | -0.527 | ||||||||
| HNSC | -0.162 | ||||||||
| LUAD | -0.059 | ||||||||
| LUSC | 0.72 | ||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Thr842 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 1.307 | ||||||||
| COAD | -0.496 | ||||||||
| HGSC | |||||||||
| ccRCC | 0.037 | ||||||||
| GBM | -1.372 | ||||||||
| HNSC | -0.652 | ||||||||
| LUAD | 1.788 | ||||||||
| LUSC | 0.167 | ||||||||
| non_ccRCC | |||||||||
| PDAC | -0.067 | ||||||||
| UCEC | -0.713 | ||||||||
| PTK2B-Tyr579 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.707 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.707 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr580 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | 0.707 | ||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | -0.707 | ||||||||
| HNSC | |||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr756 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | 0.248 | ||||||||
| HGSC | |||||||||
| ccRCC | |||||||||
| GBM | 0.853 | ||||||||
| HNSC | -1.101 | ||||||||
| LUAD | |||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr834 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer | Intensity | ||||||||
| BRCA | |||||||||
| COAD | |||||||||
| HGSC | |||||||||
| ccRCC | 0.605 | ||||||||
| GBM | -1.154 | ||||||||
| HNSC | |||||||||
| LUAD | 0.549 | ||||||||
| LUSC | |||||||||
| non_ccRCC | |||||||||
| PDAC | |||||||||
| UCEC | |||||||||
| PTK2B-Tyr849 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | -0.707 |
| HNSC | |
| LUAD | |
| LUSC | 0.707 |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | U | Uterine serous carcinoma | Phosphorylation | 36409196 |
| - | - | U | Cervical cancer/carcinoma | Phosphorylation | 24058594 |
| - | - | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 11287749 |
| - | - | U | Breast cancer | Phosphorylation | 12421874 |
| - | - | U | Head and neck squamous cell carcinoma | Phosphorylation | 22483702 |
| - | - | U | Ovarian cancer | Phosphorylation | 36217544 |
| - | - | U | Cancer | Phosphorylation | 36656716 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptM| Protein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
|---|---|---|---|---|---|---|---|---|---|
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | A431 | Imatinib | 8.2423 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | AZD4547 | 7.7576 | - | |
| Q05397 | PTK2 | P | Tyr720 | QATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | AZD4547 | 7.2101 | - | |
| Q05397 | PTK2 | P | Tyr720 | RQATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | AZD4547 | 7.1997 | - | |
| Q05397 | PTK2 | P | Ser574;Thr575;Tyr576;Tyr577 | YMEDS(ph)T(ph)Y(ph)Y(ph)K | PC-9 | AZD4547 | 1.5229 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | Gefitinib | 8.1192 | - | |
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | PC-9 | Gefitinib | 4.9948 | - | |
| Q05397 | PTK2 | P | Tyr720 | RQATVSWDSGGSDEAPPKPSRPGY(ph)PSPR | PC-9 | GeftinibAZD4547-1to80 | 9.855 | - | |
| Q05397 | PTK2 | P | Tyr570 | Y(ph)MEDSTYYK | PC-9 | GeftinibAZD4547-1to80 | 8.4574 | - | |
| Q05397 | PTK2 | P | Tyr576 | YMEDSTY(ph)YK | PC-9 | GeftinibAZD4547-1to80 | 6.6249 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.
